Skip to main navigationSkip to main content
The University of Southampton

Curve Therapeutics

Curve has developed a powerful and proprietary discovery platform that is being used to identify a new generation of cancer drugs with significant clinical potential. A spin-out from the School of Chemistry, Curve’s core technology was established in more than a decade of research within the laboratory of Professor Ali Tavassoli.

Curve’s novel platform has broad potential in drug discovery, with several key advantages over existing methods:

The core technology that underpins Curve’s platform has been successfully employed by Prof. Tavassoli’s team to discover functional inhibitors of multiple protein-protein interactions. A number of these inhibitors have been used as the starting-point to develop drug-like small molecule leads. Amongst these leads are two inhibitors of hypoxia inducible factor (HIF), a key driver of cancer cells’ ability to adapt to low oxygen conditions inside solid tumours. These lead compounds, one a first-in-class inhibitor of HIF-1 and the other a unique dual inhibitor of HIF-1 and HIF-2, are being developed towards the clinic by Curve and have significant potential in the treatment of a variety of solid tumours.

Curve is using this platform to build a pipeline of cancer drugs against disease-relevant, but previously intractable, molecular targets. The company also aims to work in partnership with pharmaceutical companies to identify novel hits and leads against their priority disease targets.

Privacy Settings